Concepedia

Ichiro Umemura

IU

Statistics

Publications

10

Citations

599

H-Index

10

Active since

1992

Affiliations

Novartis (Switzerland)(Current)

Takara (Japan)

Novartis (Japan)

Novartis (China)

Ichiro Umemura is an author at Novartis (Switzerland) specializing in pharmacology, signal transduction, and drug design.

Publications per year

1992–2023

10

Publications

10

A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor

Michihiro Takai, Ichiro Umemura, Keiko Yamasaki et al. · Biochemical and Biophysical Research Communications · 1992 · 233 citations

, , +7

An endothelin B receptor‐selective antagonist: IRL 1038, [Cys<sup>11</sup>‐Cys<sup>15</sup>]‐endothelin‐1(11–21)

Yoshihiro Urade, Yasushi Fujitani, Kyoko Oda et al. · FEBS Letters · 1992 · 99 citations · Full text

, , +13

A reversible radioligand specific for the ETB receptor: [125I]Tyr13-Suc-[Glu9,Ala11,15]-endothelin-1(8–21), [125I]IRL 1620

Tadashi Watakabe, Yoshihiro Urade, Michihiro Takai et al. · Biochemical and Biophysical Research Communications · 1992 · 77 citations

, , +6

Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2

Ha-Soon Choi, Zhicheng Wang, Wendy Richmond et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 55 citations

, , +12

Novel scaffold for cathepsin K inhibitors

Naoki Teno, Takahiro Miyake, Takeru Ehara et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 41 citations · Full text

, , +14

1–5 of 10